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Arterial occlusive events (AOEs) represent emerging complications in chronic myeloid
leukemia (CML) patients treated with ponatinib. We identified 85 consecutive CML
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CAOCCI ET AL. 297stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment,
based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels.
The 60‐month cumulative incidence rate of AOEs excluding hypertension was 25.7%.
Hypertension was reported in 14.1% of patients. The median time of exposure to
ponatinib was 28months (range, 3‐69months). Patients with a high to very high SCORE
risk showed a significantly higher incidence rate of AOEs (74.3% vs 15.2%, P < 0.001).
Patients aged ≥60 years showed a significantly higher incidence rate of AOEs (51.5%
vs 16.9%, P = 0.008). In multivariate analysis, no association was found between AOEs
and positive history of CV disease, age, dose of ponatinib, previous exposure to nilotinib,
and comorbidities. Only the SCORE risk was confirmed as a significant predictive factor
(P = 0.01; HR = 10.9; 95% C.I. = 1.7‐67.8). Patients aged ≥60 years who were treated
with aspirin had a lower incidence rate of AOEs (33.3% vs 61.8%). Among the 14
reported AOEs, 78.6% of them showed grade 3 to 4 toxicity. This real‐life study con-
firmed the increased incidence of AOEs in CML patients treated with ponatinib, with
high to very high SCORE risk. We suggest that patients aged ≥60 years who were
treatedwith ponatinib should undergo prophylaxis with 100mg/day of aspirin. Our find-
ings emphasize personalized prevention strategies based on CV risk factors.
KEYWORDS
arterial occlusive event, chronic myeloid leukemia, ponatinib, prophylaxis1 | INTRODUCTION
Ponatinib is a third‐generation tyrosine kinase inhibitor (TKI), active against
native and mutated BCR‐ABL1, indicated for the treatment of chronic
myeloid leukemia (CML) patients in every phase of the disease, resistant
and/or intolerant to dasatinib and nilotinib, with or without T315I muta-
tion.1 Unfortunately, ponatinib treatment may induce cardiovascular
adverse events (CVAEs) and, in particular, arterial occlusive events (AOEs).
In the 5‐year follow‐up of the multinational phase II Ph + ALL and CML
Evaluation (PACE) trial, the cumulative incidence rate of AOEs was 31%
in the chronic‐phase CML population; the cumulative incidence rate of
AOEs continued to increase over time, but the exposure‐adjusted inci-
dence of newly occurring AOEs remained relatively constant throughout
the study, due to the reduction of the dose since October 2013.2 The inci-
dence rate of AOEs following ponatinib treatment in real life was reported
only in a few small patient cohorts followed up for short periods, showing
variable outcomes.3-6 Risk factors associated with the development of
AOEs have been identified in basal CV risk factors and/or may include
the following: a history of previous ischemic disease,2 dose intensity and
age at starting ponatinib,7 male sex, previous history of AOEs, and previ-
ous exposure to nilotinib.5 The usefulness of the Systematic Coronary Risk
Evaluation (SCORE) risk assessment at disease baseline, a 10‐year risk esti-
mation of fatal CV disease based on sex, age, smoking, systolic pressure,
and total cholesterol level, to identify patients with increased risk of occur-
rence of AOEs during ponatinib treatment has been suggested.8,9
Given the growing interest on the occurrence of AOEs in CML
patients as off‐target effects in the long term and the emergence ofa new interdisciplinary specialty of “cardio‐oncology” focusing on the
proper stratification of CV risk in CML patients and management of
complications, ad hoc expert opinions in this field have been pub-
lished.9,10 Overall, the recommendations agree on the importance of
the CV risk stratification at baseline and suggest that certain TKIs
should be used with caution in patients with preexisting CV risk fac-
tors, highlighting the need for a careful monitoring prior to the admin-
istration of the drug and during treatment.
Moreover, in CML patients treated with ponatinib, a preventing strat-
egy with primary prophylaxis based on aspirin is still under discussion: the
use of an antiplatelet agent in CML is not supported by literature data or
by guidelines and is so far based onmedical decision on an individual basis.
We therefore reported a large real‐life cohort of Italian CML patients
treated with ponatinib outside clinical trials. The primary endpoint was to
establish the incidence of AOEs and the association with the SCORE
assessment and baseline CV risk factors. Secondary endpoints were to
evaluate the role of primary prophylaxis in preventingAOEs and to report
the management of AOE complications in the clinical practice.2 | METHODS
We identified 85 consecutive nonselected adult CML patients who were
treated with ponatinib outside clinical trials between January 2012 and
December 2017 in 17 Italian centers. Information on CV risk factors
before starting ponatinib was retrospectively collected from the review
of medical charts. To estimate the SCORE risk, all patients were




Age at diagnosis, median years (range) 53 (23‐81)
Median follow‐up, median years (range) 6.3 (0.8‐25.9)
Leukocyte ×103/uL, mean value (range) 104 (7‐500)
Hemoglobin g/dl, mean value (range) 12.7 (5.5‐16.7)











Second line 23 (27)
Third line 37 (43.5)
Fourth line 25 (29.5)
Ponatinib dose
45 mg/day 34 (40)
30 mg/day 36 (42.3)




Duration of ponatinib median months (range) 28 (3‐69)
298 CAOCCI ET AL.evaluated at diagnosis for age, gender, tobacco use, systolic pressure, and
total cholesterol serum level; patients were stratified into low to moder-
ate (SCORE ≤ 5%) or high to very high (SCORE risk >5%) CV risk. Addi-
tional risk factors were as follows: presence of diabetes, bodymass index
>24.5 kg/m2, mild or severe renal insufficiency, and dyslipidemia.
Patients were also evaluated for comorbidities and a positive anamnesis
of CV diseases, including myocardial infarction, heart failure, cardiomy-
opathy, angina, stroke, arterial hypertension, valvular heart disease, heart
arrhythmia, aortic aneurysms, peripheral artery disease, ischemic cere-
brovascular events, venous thrombosis, and thromboembolic disease.
The presence of antithrombotic prophylaxis before starting CML treat-
ment was also recorded and, according to the same indications as the
general population, defined as primary (based on the presence of risk fac-
tors) prophylaxis, mainly represented by 100 mg/day of aspirin, or sec-
ondary prophylaxis (positive history of atherothrombotic events),
represented by aspirin, other antiplatelet agents such as ticlopidine or
clopidogrel, or anticoagulant therapy. We evaluated the cumulative inci-
dence rate of AOEs (CV excluding hypertension, cerebrovascular, and
peripheral vascular) after initiating the treatment with ponatinib and their
management by the hematologists and cardiologists.
CML patients' response to TKI was evaluated according to the
European Leukemia Net recommendations.11 Molecular response
was estimated by the presence of detectable BCR‐ABL transcripts
using quantitative reverse transcription‐polymerase chain reaction
with a sensitivity of 3 logs (MR3) or deeper (MR4).12
The probability of the cumulative incidence rate of AOEs was esti-
mated after administering ponatinib. The cumulative incidence rate of
MR4 was evaluated from the start of ponatinib treatment. The log‐rank
test was used to compare two or more groups of stratified patients.
We evaluated the impact of the following variables on the incidence of
AOEs: positive anamnesis for CV disease, age≥ 60 years, ponatinib dose,
previous exposure to nilotinib, comorbidities, primary prophylaxis, and
SCORE risk.Multivariate analyseswere performed using the Cox propor-
tional hazards regression model. A P‐value <0.05was considered statisti-
cally significant. Data analysis was performed using a standard statistical
package (SPSS for Macintosh, Version 21, Chicago, IL).3 | RESULTS
3.1 | Patients' characteristics, arterial occlusive
events, and clinical outcomes
A total of 85 consecutive chronic CML patients were retrospectively
identified. The patients' characteristics are shown in Table 1. The
median age at diagnosis was 53 years (range, 23‐81 years). The Sokal
score was intermediate to high in 58.9% of patients. The median inter-
val since CML diagnosis was 6.3 years (range, 0.8‐25.9 years). The rea-
sons for treatment with ponatinib included the following: inefficacy of
previous TKI in 81.1% and intolerance in 18.9% of patients. At
ponatinib starting, 21 patients (24.7%) harbored a T415I mutation. In
the majority of cases, ponatinib was scheduled as a third‐line or subse-
quent lines of treatment. Ponatinib was administered at the followingdoses: 45 mg/day in 40% of patients, 30 mg/day in 42.3% of patients,
and 15 mg/day in 17.7% of patients, respectively.
The median time of exposure to ponatinib was 28 months (range,
3‐69 months). At the time of AOE occurrence, 14.3% of patients
received 45 mg/day of ponatinib, 64.3% of patients received
30 mg/day of ponatinib, and 21.4% of patients received 15 mg/day
of ponatinib, respectively. The median time between the start of
ponatinib treatment and the occurrence of AOEs was 16 months
(range, 1‐61 months). A positive history for CV diseases was reported
in 32 patients (37.7%). The 60‐month cumulative incidence rate of
AOEs was 25.7 ± 7%. Hypertension was reported in 14.1% of patients.
The majority of the patients (82.3%) were classified at low to interme-
diate risk (SCORE risk ≤5%) and 17.7% of patients at high to very high
risk (SCORE risk >5%) according to the SCORE risk chart evaluation.
Patients with a high to very high SCORE risk showed a significantly
higher incidence of AOEs (74.3 ± 19.7% vs 15.2 ± 6.2%, P < 0.001)
(Figure 1). Patients aged ≥60 years showed a significantly higher inci-
dence of AOEs (51.5 ± 16.6% vs 16.92 ± 6.9, P = 0.008).
FIGURE 1 Cumulative incidence of arterial occlusive events in 85
patients treated with ponatinib, according to the SCORE risk, based on
sex, age, smoking habits, systolic blood pressure, and total cholesterol
levels
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between AOEs and positive history of CV disease, age, dose of
ponatinib, previous exposure to nilotinib, and comorbidities. Only the
SCORE risk was confirmed to have a significant association
(P = 0.01; hazard ratio = 10.9; 95% confidence interval = 1.7‐67.8)
with the incidence of AOEs. Finally, the 5‐year cumulative incidence
rate of MR4 following ponatinib treatment was 40.6 ± 10.7%, and it
was not influenced significantly by AOE occurrence.FIGURE 2 Bubble chart displaying 14 occlusive events that occurred from
The diameter of the area of the bubble represent the dose of ponatinib (13.2 | Role of primary prophylaxis
Overall, 19 patients were treated with 100 mg/day of aspirin as a pri-
mary prophylaxis before starting the administration of ponatinib.
In these patients, the 25‐year overall survival rate was 94.1 ± 5.7%
in comparison with 76.4 ± 10.8% in 66 patients who did not receive
primary prophylaxis (P = NS).
No significant association was found between AOE occurrence and
primary prophylaxis. Nevertheless, in patients aged ≥60 years treated
with aspirin, we found a lower, although not statistically significant, inci-
dence rate of AOEs (33.3 ± 27.2% vs 58.6 ± 19.2%, P = NS). In six
patients aged ≥60 years taking aspirin, only one AOE was registered,
in comparison with six AOEs in 15 older patients not taking aspirin.
3.3 | Management of CV events
Overall, 26 CVAEs in 80 patients were recorded: 14 AOEs and 12
hypertension cases (Figure 2, Table 2); 13 CVAEs were graded as 3
to 4 according to the common toxicity criteria.13 At the time of
CVAEs, five patients were administered with 15 mg/day (19.2% of
CVAEs), eight with 30 mg/day (30.8% of CVAEs), and 13 patients with
45 mg/day (50% of CVAEs) of ponatinib. Dosing during AOEs is
reported in Figure 2. A higher drug dose was not associated to AOEs.
Following the CVAEs, 11 patients undergoing ponatinib treatment did
not require dose modification, four patients reduced the dose, and 11
patients discontinued the treatment. Majority of the patients were
required to undergo additional diagnostic tests such as ECG/cardiac
ultrasound, peripheral vascular Doppler ultrasound, and cranial CT;
two patients underwent coronarography, and three patients required
invasive procedures such as percutaneous transluminal angioplasty
and coronary stent application. Additional medical therapy was intro-
duced in the majority of cases.2012 to 2017 in 85 patients treated with different doses of ponatinib.
5, 30, or 45 mg)
TABLE 2 Cardiovascular profile of 85 patients and management of 26 cardiovascular adverse events
N° (%) N° (%)
CV risk factors TKI combinations in CVAEs
Hypertension 20 (23.5) Ima‐Pona 1 (1.2)
Dyslipidemia 24 (28.2) Dasa‐Pona 3 (3.5)
Obesity (BMI >24.5) 49 (57.6) Nilo‐Pona 1 (1.2)
Severe renal insufficiency 1 (1.2) Ima‐Dasa‐Pona 5 (5.8)
Diabetes 12 (14.1) Ima‐Nilo‐Pona 5 (5.8)
SCOREa risk ≤5% (low to int.) 70 (82.3) Ima‐Dasa‐Nilo‐Pona 5 (5.8)
SCORE risk >5% (high to very high) 15 (17.7) Ima‐Nilo‐Dasa‐Pona 5 (5.8)
Ima‐Bosu‐Ima‐Pona 1 (1.2)
CVD before ponatinib treatment
Myocardial infarction/angina 4 (4.7) Toxicity grading CVAEs
Arrhythmia 3 (3.5) Grade 1‐2 13 (15.3)
Other cardiac diseasesb 5 (5.8) Grade 3‐4 13 (15.3)
Peripheral arterial disease 0 (0) Grade 5 0 (0)
Stroke 0 (0)
Hypertension 20 (23.5) Ponatinib dose modification
Peripheral venous disease 0 (0) Unchanged 11 (13)
Primary prophylaxisc 17 (20) Reduced 4 (4.7)
Secondary prophylaxisd 6 (7) Interrupted 11 (13)
CVAEs following ponatinib Additional tests requested
Number of CVAEs 26 (30.5) Coronarography 2 (2.3)
Number of AOEs 14 (16.5) ECG/cardiac ultrasound 12 (14.1)
Myocardial infarction/angina 2 (2.3) Cardiac angio‐MR/TAC 4 (4.7)
Arrhythmia 1 (1.2) Peripheral vascular Doppler ultrasound 2 (2.3)
Other cardiac diseasese 3 (3.5) Nothing 7 (8.2)
Peripheral arterial diseasef 5 (5.8)
Stroke 3 (3.5) Therapies introduced
Hypertension 12 (14.1) Coronary stents 2 (2.3)
PTAf peripheral artery 1 (1.2)
Ponatinib dose at CVAEs Antiplatelet 8 (9.4)
45 mg/day 13 (15.3) Anticoagulant 1 (1.2)
30 mg/day 8 (9.4) Antiarrhythmic 1 (1.2)
15 mg/day 5 (5.8) Other drugs® 14 (16.5)
No further action 2 (2.3)
Line of treatment
Second line 5 (5.8) Total CV‐related deaths 0 (0)
Third line 10 (11.8)
Fourth line 11 (13)
Abbreviations: AOEs, arterial occlusive events; CVAES, cardiovascular adverse events; CVD, cardiovascular disease.
aBased on sex, age, smoking, systolic pressure, and cholesterol level.
bValvulopathy and dilated cardiomyopathy.
cAspirin.
dAspirin, clopidogrel, and ticlopidine.
eQT elongation and cardiac failure.
fPAOD (peripheral arterial occlusive disease) and atheromatous carotid disease.
gPTA (percutaneous transluminal angioplasty).
Diuretics, calcium channel blockers, ACE inhibitors, and beta blockers.
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AOEs represent off‐target relevant complications of TKIs, particularly
second‐generation and third‐generationTKIs.14 Nilotinib and ponatinib
interact with a considerable number of clinically relevant vascular tar-
gets implicated in endothelial cell survival and angiogenesis.15
Ponatinib was temporarily suspended in 2013 as its administration
resulted in the occurrence of CV thrombotic events, and since then, sev-
eral publications have provided general management recommendations
for patients eligible to receive ponatinib.9,10 The cumulative incidence
rate of AOEs reported by the 5‐year follow‐up of PACE trial was 31%
(serious AOEs, 26%) in the chronic‐phase CML population; in this
report, the higher cumulative incidence rate correlated with the longer
duration of treatment with ponatinib.2 Independent variables signifi-
cantly associated with AOEs were basal CV risk factors and a history
of ischemic disease; notably, even after a suggested preemptive dose
reduction in October 2013, the percentage of patients who had experi-
enced the first occurrence of AOE was similar in the cohort of patients
who underwent the dose reduction and those who maintained treat-
ment at the same dose.2 Company‐sponsored CML randomized clinical
trials investigating ponatinib efficacy and safety might have important
selection biases because they are not designed to register baseline tra-
ditional CV risk factors and because of their correlationwithAOEs.Nev-
ertheless, a systematic review and multivariate analysis from a pooled
population including three clinical trials showed that dose intensity, his-
tory of ischemic disease, and age were the strongest independent pre-
dictors of increased risk of AOE; this model predicted an
approximately 33% reduction in the risk of AOE for each 15 mg/day
decrease in average ponatinib dose intensity.7
Recently published data originating from real life, based on a small
population cohort study, reported the absence or very low incidence
of AOEs.3,4 The authors enumerated the following possible reasons
of these unexpected data: the limited follow‐up, a better selection of
patients with few concomitant comorbidities, a lack of preexisting
CV risk factors at baseline, a low starting dose of the drug in 40% of
patients, the number of TKI lines of treatment,3 and significantly youn-
ger population in comparison with the PACE trial.4 Other recent stud-
ies from real life reported a variable incidence rate of CVAEs from
23% to 56%, suggesting that male sex, previous history of AOEs,
and previous exposure to nilotinib are considered risk factors.5,6
Overall, these observations suggested the need to customize treat-
ment approaches, considering the appropriate TKI selection according
to baseline CV risk factors.
We evaluated a retrospective large cohort of 85 consecutive CML
patients managed in Italy and treated with ponatinib in subsequent
lines of treatment and found a 5‐year AOE (excluding hypertension)
cumulative incidence rate of 25.7%, similar to the PACE trial (31%),
which included hypertension as one of the AOEs. Our study showed
that patients aged ≥60 years represented a risk factor in a univariate
analysis. Age was found to be associated to AOEs also in the published
multivariate analysis including 671 ponatinib‐treated patients.7 More-
over, we confirmed for the first time that the SCORE risk chart, based
on sex, age, smoking, systolic pressure, and total cholesterol level, inthe setting of ponatinib‐treated patients has an independent predic-
tive value; indeed, patients with a high to very high risk score reported
a significantly higher incidence of AOEs (74.3% vs 15.2%, P < 0.001),
and this risk factor remained significant also in multivariate analysis
(Figure 1). Overall, personalized strategies to minimize the risk of
AOEs should be thoroughly screened; this could be particularly impor-
tant for the elderly patients with multiple comorbidities. No significant
differences in AOE incidence were found according to the different
TKI combinations registered in the subsequent lines of treatment or
the different doses of ponatinib (15 mg/day, 30 mg/day, 45 mg/day)
received by the patients (Table 2). Overall, ponatinib efficacy was con-
firmed in this cohort of heavily pretreated patients, reaching a 60‐
month cumulative incidence rate of 40.6% in MR4, and this outcome
was not influenced by the occurrence of AOEs.
Among the 14 reported AOEs, 78.6% of them showed a grade of 3
to 4 toxicity. The frequencies of CV, cerebrovascular, and peripheral
vascular disease (PAOD or atheromatous carotid disease) were 14.3%,
21.4%, and 35.7%, respectively. The dose of ponatinib was reduced in
7.1% of patients, and ponatinib administration was discontinued in
78.6% of patients. Additional diagnostic tests were requested in most
cases, such as coronarography, ECG/cardiac ultrasound, cardiac
angio‐MR/CT, and peripheral vascular Doppler ultrasound. Additional
drugs were administered in themajority of patients, and invasive proce-
dures (coronary stents and percutaneous transluminal angioplasty)
were performed in three patients (Table 2). Ideally, management and
treatment of these patients should be carried out in close collaboration
with cardiologists, angiologists, and vascular surgeons.
Notably, primary prophylaxis with 100 mg/day of aspirin may rep-
resent an option for this category of patients, aiming at reducing the
incidence of atherothrombotic events.
Although the role of aspirin is still a matter of debate and no data
have thus far been published, we observed a lower, although not statis-
tically significant, incidence rate of AOEs (16.9% vs 51.5%) in patients
aged ≥60 years who were treated with 100 mg/day of aspirin.
Future prospective studies are needed to further corroborate our
preliminary findings.
Given the long‐term (often lifelong) TKI treatment required by the
majority of CML patients, who nowadays can expect a survival similar
to that of their peers from the general population,16 a personalized
treatment approach, based not only on disease‐free survival but also
on safety and quality of life, is needed.17-19 This aim requires the avail-
ability of a cardio‐oncology facility, with cardio‐oncology a discipline
based on the collaboration between cardiologists, hematologists, and
other medical specialists with the aim of preventing, monitoring, diag-
nosing, and treating AOEs before, during, and after treatment. Several
steps to prevent AOEs in CMLpatients treatedwithTKIs have been sug-
gested.20 Besides the management of modifiable CV risk factors, pri-
mary prophylaxiswith aspirin has been proposed for “selected” patients.
In conclusion, this study confirms the increased risk of AOEs in
CML patients treated with ponatinib in real life, harboring a high to
very high SCORE risk. Our findings emphasize the need of personal-
ized prevention strategies based on CV risk factors in close collabora-
tion with cardio‐oncologists, angiologists, and vascular surgeons. We
302 CAOCCI ET AL.suggest that patients aged ≥60 years treated with ponatinib should
undergo a prophylaxis with 100 mg/day of aspirin. Data on the effi-
cacy of the primary prophylaxis need to be confirmed in larger cohorts
of patients and in prospective randomized trials.DECLARATIONS
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